KC-6506

CTLL-2-PD1 Cell Line

×
Please enable JavaScript in your browser to complete this form.
62861
Home » CTLL-2-PD1 Cell Line

Background of CTLL-2-PD1 Cell Line

PD-1, human programed cell death 1 protein, is a receptor belonging to immunoglobulin superfamily which is expressed primarily on activated T cells. NK cells, B cells, and monocytes. PD-1 interaction with its ligands, PD-L1 and PD-L2, leads to downregulation of T cell responses, including T cell proliferation and cytokine production, and limits immune-destruction of tissues. The interaction between PD-1 and its ligands, thus plays a role in maintaining the balance between immune activation and tolerance, potentially including tumor tolerance.

Specifications

Catalog NumberKC-6506
Cell Line NameCTLL-2-PD1 Cell Line
NCBI/UniProt Accession NumberQ15116
Clone Number6#
Host Cell LineMouse CTLL-2 Cell Line
DescriptionStable CTLL-2 cell line expressing exogenous human PD1 gene
QuantityTwo vials of frozen cells (≥2-106/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10% FBS +2μg/mL Puromycin+100ng/mL Mouse IL-2
Selection MarkerPuromycin
MorphologyLymphoblast-like
SubcultureSplit saturated culture 1:4-1:8 every 2-3 days
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 24 hours
Mycoplasma StatusNegative

Cell Line Generation

CTLL-2-PD1 cell line was generated using a lentiviral vector expressing the human PD1 sequence.

Characterization

Figure 1: Characterization of human PD1 overexpression in the CTLL-2-PD1 stable clone using FACS.

Figure 2: Characterization of human PD1 in the CTLL-2-PD1 stable clone using PCR sequencing.

Cell Resuscitation

  1. Pre-warm complete culture medium (RPMI1640+10% FBS +2μg/mL Puromycin+100ng/mL Mouse IL-2) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO2 incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4-1:8 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×106 cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

1. Sunshine, J. & Taube, J. M. PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology 23, 32–38 (2015).
2. Boussiotis, V. A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 375, 1767–1778 (2016).
3. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443–2454 (2012).
Please enable JavaScript in your browser to complete this form.